ImmunityBio Secures Exclusive U.S. Supply of Tokyo-172 BCG to Address Bladder Cancer Shortage

summarizeSummary

ImmunityBio has entered an exclusive agreement with Japan BCG Laboratory to develop and supply the Tokyo-172 strain of BCG in the U.S., aiming to alleviate the long-standing BCG shortage for bladder cancer treatment.

check_boxKey Events · Product Development and Regulatory · IBRX

• Exclusive Supply Agreement

  ImmunityBio secured exclusive U.S. rights to develop, import, and commercialize the Tokyo-172 strain of BCG from Japan BCG Laboratory for 10 years post-FDA approval.

• Addresses BCG Shortage

  This agreement provides a second potential source of BCG for the U.S. market, aiming to resolve a critical, decade-long supply shortage for bladder cancer treatment.

• Leverages Phase III Data

  The Tokyo-172 strain is supported by positive Phase III data showing non-inferiority to TICE BCG in BCG-naïve high-grade non-muscle invasive bladder cancer.

• Regulatory Pathway

  ImmunityBio will lead all U.S. regulatory submissions, including engaging with the FDA for BLA approval, with no upfront payments to JBL.

auto_awesomeAnalysis · IBRX · Life Sciences

This agreement is highly significant as it positions ImmunityBio to become a primary supplier of BCG, a critical component for bladder cancer therapy, in the U.S. The Tokyo-172 strain has demonstrated non-inferiority in a Phase III trial, and securing exclusive rights to its development and commercialization could substantially expand ImmunityBio's market presence in oncology, complementing its existing ANKTIVA product. This strategic move addresses a decade-long supply issue, potentially improving patient access and strengthening the company's revenue streams upon FDA approval.